Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

PURPOSE: FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) are associated with early relapse and poor survival. Quizartinib potently and selectively inhibits FLT3 kinase activity in preclinical AML models. PATIENTS AND METHODS: Quizartinib wa...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Cortes, Jorge E., Kantarjian, Hagop, Foran, James M., Ghirdaladze, Darejan, Zodelava, Mamia, Borthakur, Gautam, Gammon, Guy, Trone, Denise, Armstrong, Robert C., James, Joyce, Levis, Mark
格式: Artigo
語言:Inglês
出版: American Society of Clinical Oncology 2013
主題:
Original Reports
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3804291/
https://ncbi.nlm.nih.gov/pubmed/24002496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.48.8783
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍